Enbrel (etanercept) / Pfizer, Amgen  >>  Phase 4
Welcome,         Profile    Billing    Logout  

55 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Enbrel (etanercept) / Pfizer, Amgen
ChiCTR1900024408: Ruxolitinib Combined With Etanercept for Patients With Corticosteroid-Refractory Graft Versus Host Disease After Allogeneic Stem Cell Transplantation: A Multi-Center, Open-Label, Prospective Study

Completed
4
40
 
ruxolitinib
The First Affiliated Hospital, College of Medicine, Zhejiang University; The First Affiliated Hospital, College of Medicine, Zhejiang University, The First Affiliated Hospital, College of Medicine, Zhejiang University
acute and chronic graft versus host disease
 
 
NCT00016575: ENBREL(R) (Etanercept) Safety Study in Children With Juvenile Rheumatoid Arthritis

Active, not recruiting
4
600
NA
ENBREL(R) (etanercept)
Amgen, Immunex Corporation
Juvenile Rheumatoid Arthritis
 
 
2007-007170-30: Untersuchung des Phänotyps und der Funktion proinflammatorischer dendritischer Zellen während einer Therapie der Psoriasis vulgaris mit einem TNFalpha Antagonisten Investigation of phenotype and function of proinflammatory dendritic cells during therapy of psoriasis with TNF alpha antagonists

Ongoing
4
10
Europe
Etanercept, Solution for injection, Enbrel
Technical University of Dresden, faculty of medicine
Psoriasis vulgaris
 
 
2008-000106-37: Studies on the combined treatment using etanercept and ultraviolet B for patients with moderate to severe psoriasis vulgaris

Ongoing
4
20
Europe
Solution for injection, Enbrel 25 mg®
Klinik für Dermatologie und Allergologie der RUB, St. Josef Hospital
Psoriasis vulgaris (Plaque-Typ)
 
 
2009-015403-95: A pilot trial of noninvasive assessment of methotrexate hepatotoxicity in the course of pharmacokinetically guided pharmacotherapy of psoriasis with methotrexate and folic acid

Ongoing
4
90
Europe
ACIDUM FOLICUM LECIVA, methotrexate 2.5 mg tablets, EU/1/99/116/001, Coated tablet, Powder for solution for injection, Powder for injection*, Tablet, ACIDUM FOLICUM LECIVA, REMICADE 100 MG, ENBREL 50 MG
Faculty Hospital Hradec Králové
moderate-severe and severe plaque psoriasis
 
 
2005-000707-34: The induction of apoptosis by anti-psoriatic treatments

Ongoing
4
100
Europe
INFLIXIMAB, ETANERCEPT, METHOTREXATE SODIUM TABLETS, CICLOSPORIN A CAPSULES, HYDROXYCARBAMIDE, ACITRETIN, CALCIPOTRIOL, HYDROMOL, SHORT CONTACT DITHRANOL IN HYDROMOL, DITHRANOL IN LASSAR'S PASTE, STRONG COAL TAR SOLUTION IN HYDROMOL, PUVASORALEN-8, Powder for injection*, Powder and solvent for solution for injection, Tablet, Capsule*, Cream, Ointment, REMICADE, ENBREL, METHOTREXATE, NEORAL, HYDREA, NEOTIGASON, DOVONEX CREAM, DOVONEX OINTMENT, HYDROMOL OINTMENT, METHOXSALEN
The Newcastle upon Tyne Hospitals NHS Trust
Psoriasis
 
 
2011-005534-19: The effect of peri-operative anti-inflammatory treatment on postoperative muscle weakness and muscle fatigue in elderly surgery patients Het effect van peri-operatieve anti-inflammatoire behandeling op postoperatieve spierzwakte en spiervermoeidheid bij oudere chirurgiepatiënten.

Ongoing
4
100
Europe
Etanercept, Molsidomine, Fenofibrate, Powder and solvent for solution for injection, Capsule, Enbrel, Coruno, Lipanthyl
Vrije Universiteit Brussel, Vrije Universiteit Brussel
Post-operative muscle weakness, fatigue and inflammation., Muscle weakness, fatigue and inflammation following surgery., Body processes [G] - Physiological processes [G07]
 
 
2012-004631-22: TapERA: Tapering Etanercept in Reumatoid Artritis.

Ongoing
4
120
Europe
Enbrel, EMEA/H/C000262, Solution for injection in pre-filled syringe, Enbrel
University Hospitals Leuven, department of rheumatology, University Hospitals Leuven
reumatoid arthritis, reumatoid arthritis, Diseases [C] - Musculoskeletal Diseases [C05]
 
 
2012-005809-53: What is the biologic drug concentration required to maintain stable disease activity in psoriasis?

Ongoing
4
65
Europe
adalimumab, etanercept, Ustekinumab, Solution for injection, Humira, Enbrel, Stelera
Psoriasis, Psoriasis, Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02]
 
 
2013-003956-18: Prevention of disease flares by risk-adapted stratification of therapy withdrawal in juvenile idiopathic arthritis (JIA) Preventie van recidieven door risico-aangepast staken van de behandeling bij juveniele idiopathische artritis (JIA)

Ongoing
4
325
Europe
enbrel, humira, orencia, methotrexate, Methotrexate, EU/1/99/126/001, EU/1/03/256/001, EU/1/07/389/001, RVG 28636, RVG 104433, Injection, Infusion, Tablet, enbrel, humira, orencia, methotrexate
University Medical Center Utrecht, Interdisziplinäre Zentrum für Klinische Forschung Münster
juvenile idiopathic arthritis juveniele idiopathische artritis, juvenile (rheumatoid) arthritis jeugdreuma, Diseases [C] - Musculoskeletal Diseases [C05]
 
 
2015-002284-42: The rationale for this study is to gain insight in the extent and impact of immunogenicity of TNF inhibitors in the European daily clinical practice. Furthermore, an European wide database will give insight in factors influencing immunogenicity and treatment outcome in terms of disease activit

Ongoing
4
1650
Europe
etanercept, adalimumab, certolizumab pegol, golimumab, infliximab, Injection, Infusion, Enbrel, Humira, Cimzia, Simponi, Remicade
READE, PFIZER
rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and psoriasis., rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and psoriasis., Not possible to specify
 
 
2004-004691-37: Etanercept in Psoriasis and Psoriatic Arthritis: a single center, open-label study in 15 patients.

Ongoing
4
15
Europe
Enbrel (etanercept), 0881, Enbrel (etanercept) A centralised product with Marketing Authorisation in 25 EU Member States EU MA granted 3 February 2000, Enbrel (etanercept) A centralised product with Marketing Authorisation in 25 EU Member States EU MA granted 3 February 2000
St Vincents University Hospital
Psoriasis and Psoriatic Arthritis
 
 
2006-002349-35: Estudio piloto randomizado, doble ciego, multicéntrico a 12 semanas para evaluar el efecto de etanercept 100mg y 50mg semanales en sujetos con espondilitis anquilosante.A 12-week randomized, double-blind, multicenter pilot study to evaluate the effect of etanercept 100 mg and 50 mg weekly in subjects with ankylosing spondylitis.

Ongoing
4
108
Europe
Etanercept, 0881, Enbrel, Enbrel
Wyeth Farma S.A.
Espondilitis anquilosanteAnkylosing spondylitis
 
 
2006-000363-28: DIFFERENTIATING THE MECHANISM OF ACTION OF ANTI TNF-alpha AGENTS

Ongoing
4
40
Europe
Infliximab, Etanercept, Remicade, Enbrel, Remicade, Enbrel
Greater Glasgow Health Board, Glasgow University
Rheumatoid arthritis and Psoriatic arthritis
 
 
2006-006275-21: A Randomised, Pragmatic, Open-label study of Adalimumab versus Etanercept for Rheumatoid Arthritis.

Ongoing
4
124
Europe
Humira, Enbrel, Humira, Enbrel
University Hospital Birmingham NHS Foundation Trust
Rheumatoid Arthritis
 
 
2007-001190-28: Randomised controlled trial of tumour-necrosis-factor inhibitors against combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis

Ongoing
4
190
Europe
Methotrexate, Sulfasalazine, Hydroxychloroquine, Ciclosporin, Leflunomide, Sodium aurothiomalate (intramuscular gold), methylprednisolone, Prednisolone, Infliximab, Etanercept, Adalimumab, Azathioprine, Penicillamine, Methotrexate, Sulfasalazine, Hydroxychloroquine, Ciclosporin, Leflunomide, Sodium aurothiomalate (intramuscular gold), methylprednisolone, Prednisolone, Infliximab, Etanercept, Adalimumab, Azathioprine, Penicillamine,
King\'s College London
Rheumatoid Arthritis
 
 
2006-006562-42: An Observational and Exploratory Study to determine the effect of anti TNF Biologic Treatment in Rheumatoid Cachexia

Ongoing
4
32
Europe
Etanercept 50mg, Enbrel, Enbrel
Derby Hospitals NHS Foundation Trust
Cachexia in patients with Rheumatoid arthritis.
 
 
2007-000593-24: An Open-Label, Observational Study of the Effects of Anti-TNF Therapy on Peripheral Blood and Synovial Biomarkers in Patients with Active Rheumatoid Arthritis.

 
4
26
Europe
Enbrel, Humira, Enbrel, Humira
F. Hoffmann-La Roche Ltd, F.Hoffmann-La Roche Ltd
Rheumatoid Arthritis.
 
 
2007-007888-24: Open-label Study to Evaluate the EULAR-RAID Score, Rheumatoid Arthritis Impact of Disease Score, in Rheumatoid Arthritis Patients Eligible to Etanercept and Who Will Receive Etanercept.

Ongoing
4
101
Europe
ENBREL, ENBREL
Wyeth Pharmaceuticals France
RHEUMATOID ARTHRITIS
 
 
2008-006227-31: Inflammatory Topoproteome of Psoriasis under Etanercept Treatment

Ongoing
4
6
Europe
Enbrel 50 mg Fertigspritze (= ready for use syringe for s.c. injection), Enbrel 50 mg Fertigspritze (= ready for use syringe for s.c. injection)
Medical Faculty, Otto-von-Guericke-University Magdeburg
Patients with a severe psoriasis will be treated with Enbrel (Etanercept) 2 x 50 mg s.c. per week over 12 weeks (n = 6 patients). The treatment follows rigorously the approved label of the drug. The design of the study deviates from the approved label status in the only regard that within the course of the treatment per patient i) 5 skin biopsies with a horizontal diameter of 6 mm are taken in local anesthesia and ii) 4 peripheral venous blood drawings of 10 ml, each, are performed.
 
 
2008-007492-24: An independent prospective randomised controlled trial comparing the efficacy and cost effectiveness of infliximab and etanercept in \'high need\' patients with moderate to severe chronic plaque type psoriasis

Ongoing
4
120
Europe
Remicade, Enbrel, Remicade, Enbrel
Academic Medical Center
Patients with moderate to severe chronic plaque type psoriasis (Psoriasis Area and Severity Index (PASI > 10) and/or Body Surface Area (BSA) > 10) who failed or have contraindications and/or are intolerant to ultraviolet therapy, methotrexate or cyclosporin.
 
 
2008-005450-20: The cost-effectiveness of abatacept, rituximab or anti-TNF alpha for patients with rheumatoid artritis.

Ongoing
4
33
Europe
Remicade (infliximab), Humira (adalimumab), Enbrel (etanercept), Mabthera (rituximab), Orencia (abatacept), Remicade (infliximab), Humira (adalimumab), Enbrel (etanercept), Mabthera (rituximab), Orencia (abatacept)
Radboud University Nijmegen Medical Centre, department of Rheumatic Diseases
Rheumatoid arthritis
 
 
2009-015099-86: Comparison of efficacy, safety and costs of outpatient biological treatment for psoriasis in daily clinical practice.

Ongoing
4
200
Europe
Humira, Enbrel, Humira, Enbrel
Radboud University Nijmegen Medical Centre
Psoriasis
 
 
2009-011397-14: Effect of anti-TNF-alpha therapy on endothelial progenitor cells and endothelial dysfunction in patients with psoriasis without risk factors for atherosclerosis

Ongoing
4
20
Europe
enbrel, Enbrel, Enbrel
Technical University of Dresden
Psoriasis vulgaris
 
 
2009-015653-20: Prospective study on the effects of etanercept treatment in patients with rheumatoid arthritis who are naïve for TNF-alpha blocking therapy and patients who do not respond (anymore) to prior treatment with other anti-TNF-alpha medication

Ongoing
4
100
Europe
Etanercept, etanercept, etanercept
rheumatoid arthritis
 
 
2010-020913-10: An open label, pilot, multi-centre, step-down, randomised controlled trial to examine whether Etanercept 25mg once weekly is effective in maintaining a clinical response in patients with Ankylosing Spondylitis who have responded to 50mg once weekly

Ongoing
4
50
Europe
Enbrel, Enbrel®, Enbrel, Enbrel®, Enbrel
Norfolk & Norwich University Hospitals NHS Foundation Trust
Ankylosing spondylitis
 
 
2010-020738-24: To see whether for patients with established rheumatoid arthritis that have already achieved a good response to Tumour Necrosis Factor Inhibitor (TNF inhibitor) treatment, whether the treatment be tapered to a minimum dose without affecting the control of disease activity.

Ongoing
4
99
Europe
Etanercept, Adalimumab, Enbrel pre-filled pen, Humira, Enbrel pre-filled syringe, Enbrel pre-filled pen, Humira, Enbrel pre-filled syringe
King\'s College London
Patients with established Rheumatoid arthritis
 
 
2012-004482-40: Evaluation of a protocol for the reduction of doses in patients with rheumatoid arthritis (RA) in clinical remission in treatment with biological therapies Evaluación de un protocolo para la disminución de dosis en pacientes con Artritis Reumatoide (AR) en remisión clínica en tratamiento con terapias biológicas

Ongoing
4
28
Europe
Infliximab, Adalimumab, Etanercept, Certolizumab Pegol, Golimumab, Abatacept, Tocilizumab, HUMIRA, ENBREL, CIMZIA, SIMPONI, ORENCIA, RoActemra, HUMIRA, ENBREL, CIMZIA, SIMPONI, ORENCIA, RoActemra
FRANCISCO J. BLANCO GARCÍA, FRANCISCO J. BLANCO GARCIA
Evaluation of the clinical utility of a standardized protocol of strategies for the reduction of doses in patients with rheumatoid arthritis in clinical remission at treatment with biologic therapies Evaluación de la utilidad clínica de un protocolo estandarizado de estrategias para la disminución de dosis en pacientes con Artritis Reumatoide en remisión clínica a tratamiento con terapias biológicas
 
 
2015-004173-32: Personalized medicine: Administration of TNF-alpha inhibitor treatment due to serum concentration measuring. Individualiseret behandling: dosering af TNF-alfa hæmmende behandling efter serumkoncentrationsmålinger.

Ongoing
4
500
Europe
Solution for injection/infusion in pre-filled syringe, Solution for infusion, Enbrel, Humira, Remsima, Benepali, Remicade
Department of Clinical Biochemestry, Aarhus University Hospital, Aarhus University Hospital
Rheumatic diseases, Rheumatic diseases, Body processes [G] - Immune system processes [G12]
 
 
2015-000943-17: Dose decrease of biologics for psoriasis Dosis afbouwen van biologics voor psoriasis

Ongoing
4
120
Europe
Injection, Humira (adalimumab), Enbrel (etaneracept), Stelara (ustekinumab)
Radboudumc, Zonmw
Adult Patients diagnosed psoriasis vulgaris Volwassenen gediagnosticeerd met psoriasis vulgaris, Psoriasis Psoriasis, Diseases [C] - Skin and Connective Tissue Diseases [C17]
 
 
2007-005464-26: Devlopment of Heart and blood vessel problems in patients with conditions which cause long-term, widespread, inflammation in the body.

Ongoing
4
100
Europe
Cimzia, Remicade, Enbrel, Humira, Cimzia, Remicade, Enbrel, Humira, Cimzia
Kings College London, Guys and St Thomas\'NHS Foundation Trust, Guy's and St Thomas' NHS Foundation Trust BRC
Rheumatoid Arthritis
 
 
2016-003129-40: Remission after suspension of TNF alpha therapies in RA Remissione dopo terapia con farmaci Anti TNF in pazienti affetti da Artrite Reumatoide

Ongoing
4
60
Europe
HUMIRA (ADALIMUMAB), CIMZIA (Certolizumab Pegol), ENBREL (Etanercept), REMICADE (INFLIXIMAB), SIMPONI (GOLIMUMAB), [NA], [-], Solution for injection, Powder and solvent for solution for injection, Powder for solution for injection, HUMIRA - 40 MG SOLUZIONE INIETTABILE USO SOTTOCUTANEO 2 SIRINGHE PRERIEMPITE 0.8 ML + 2 TAMPONI IMBEVUTI DI ALCOL IN 1 BLISTER, CIMZIA - 200MG-SOLUZIONE INIETTABILE-USO SOTTOCUTANEO-SIRINGA PRERIEMPITA(VETRO) 1ML 6(3X2) SIRINGHE PRERIEMPITE+6(3X2) SALVIETTINE IMBEVUTE DI ALCOOL, ENBREL - 50 MG POLV SOLUZ INIET SOTTOC. POLV. FLAC VETRO SOLV. SIRI. VET. SOLV 1 ML (50 MG/ML) 12 FLAC+12 SIRI. PRE+12 AGHI+12 ADAT PER FLAC+24 TAMP. PRE INIEZ, REMICADE - 100 MG POLVERE PER CONCENTRATO PER INFUSIONE ENDOVENOSA 1 FLACONE VETRO 20 ML USO EV, SIMPONI - 50 MG-SOLUZIONE PER INIEZIONE IN PENNA PRERIEMPITA-USO SOTTOCUTANEO-PENNA PRERIEMPITA(VETRO) -0.5 ML 3 (3X1) PENNE PRERIEMPITE
AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA, AIFA - Italian Medicines Agency
RHEUMATOID ARTHRITIS (RA) PATIENTS PAZIENTI AFFETTI DA ARTRITE REUMATOIDE (AR), RHEUMATOID ARTHRITIS (RA) PATIENTS PAZIENTI AFFETTI DA ARTRITE REUMATOIDE (AR), Diseases [C] - Musculoskeletal Diseases [C05]
 
 
2017-001970-41: Dose reduction and withdrawal of biological therapy in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: Protocol for a 18 months multi-centre trial

Ongoing
4
180
Europe
Abatacept, Adalimumab, Certolizumab pegol, Etanercept, Golimumab, Infliximab, Tocilizumab, L04AA24, L04AB04, L04AB05, L04AB01, L04AB06, L04AB02, L04AC07, Concentrate for solution for injection, Concentrate and solvent for solution for infusion, Concentrate and solvent for solution for injection, Concentrate and solvent for suspension for injection, Orencia, Humira, Cimzia, Enbrel, Benepali, Simponi, Remsima, Remicade, RoActemra, Inflectra, Imraldi, Amgevita
MD, PhD Salome Kristensen, The Danish Regions (Regionernes Medicinpulje), The Department of Rheumatology at Aalborg University Hospital, Health Science Research Fund of the Region of Northern Jutland
Rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis, Rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis (arthritis of the spine), Diseases [C] - Musculoskeletal Diseases [C05]
 
 
ChiCTR-OPB-17013924: The very early response predict prognosis in active axial spondyloarthritis patients treated with tumor necrosis factor(TNF)-α blocker

Recruiting
4
30
 
etanercept
Ren Ji Hospital South Campus, Shanghai Jiaotong University School of Medicine; Ren Ji Hospital South Campus, Shanghai Jiaotong University School of Medicine, Shanghai municipal commission of health and family planning
axial spondyloarthritis
 
 
2017-003900-28: A Stratification trial to determine key immunological factors predicting Tofacitinib efficacy and drug free remission in Psoriatic Arthritis (PsA). TOFA-PREDICT TOFA-PREDICT: Onderzoek naar biomarkers die de effectiviteit van het geneesmiddel Tofacitinib bij de behandeling van artritis psoriatica kunnen voorspellen

Ongoing
4
200
Europe
Tablet, Injection, Solution for injection, XELJANZ, Methotrexate, Enbrel
UMC Utrecht, Pfizer
psoriatic arthritis artritis psoriatica, psoriatic arthritis artritis psoriatica, Diseases [C] - Musculoskeletal Diseases [C05]
 
 
2017-001695-26: Effectiveness and safety of biological drugs in psoriasis Efficacia e sicurezza dei farmaci biologici nella psoriasi

Not yet recruiting
4
154
Europe
Etanercept, Ustekinumab, ustekinumab, [xxxx], Solution for injection, STELARA - 45 MG - SOLUZIONE INIETTABILE IN SIRINGHE PRERIEMPITE - USO SOTTOCUTANEO - SIRINGA PRERIEMPITA(VETRO) O,5 ML(90MG/ML) 1 SIRINGA PRERIEMPITA DA 0.5ML, STELARA - 90 MG - SOLUZIONE INIETTABILE IN SIRINGHE PRERIEMPITE - USO SOTTOCUTANEO - SIRINGA PRERIEMPITA(VETRO) 1 ML(90MG/ML) 1 SIRINGA PRERIEMPITA DA 1 ML
ISTITUTI FISIOTERAPICI OSPITALIERI, AIFA - Italian Medicines Agency
Moderate to severe psoriasis and joint disease Psoriasi volgare da moderata a severa e artrite psoriasica, diffuse psoriasis psoriasi volgare diffusa, Diseases [C] - Skin and Connective Tissue Diseases [C17]
 
 
2018-003432-72: Dose reduction and withdrawal of TNF inhibitors in patients with Psoriatic Arthritis and Axial Spondyloarthritis Afbouwen en stoppen van TNF remmers bij patiënten met Artritis Psoriatica en Axiale Spondylartritis.

Ongoing
4
234
Europe
Adalimumab, Certolizumab, Etanercept, Golimumab, Infliximab, Solution for injection/infusion, Tumor Necrosis Factor alpha (TNF-a) Inhibitors: Adalimumab, Certolizumab, Etanercept, Golimumab, Infliximab
Sint Maartenskliniek, Sint Maartenskliniek
Adults diagnosed with Psoriatic Arthritis en Axial Spondyloarthritis. Volwassenen gediagnosticeerd met artritis psoriatica en axiale spondylartritis., Psoriatic arthritis and Axial Spondyloarthritis Artritis psoriatica en axiale spondylartritis, Diseases [C] - Immune System Diseases [C20]
 
 
2018-004558-30: Synovial ultrasound as primary outcome in a 3-arm, randomized, open-label, parallel active controlled, multicenter international study comparing baricitinib, alone and combined with MTX versus TNF-alfa inhibitor in rheumatoid arthritis patients: Searching for synovium predictors of response. Ultrasonido sinovial como resultado principal en un estudio internacional, multicéntrico, aleatorizado, abierto de 3 brazos, con control activo de grupos paralelos, comparando baricitinib solo y combinado con metotrexato frente a un inhibidor TNF-α en pacientes con artritis reumatoide: Buscando predictores sinoviales de respuesta.

Not yet recruiting
4
186
Europe
Olumiant, Enbrel, Metotrexato, Coated tablet, Powder and solvent for solution for injection, Olumiant, Enbrel
Fundación Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz, Lilly S.A., Spain
rheumatoid arthritis Artritis reumatoide, rheumatoid arthritis Artritis reumatoide, Diseases [C] - Musculoskeletal Diseases [C05]
 
 
2018-004539-54: Capability of Tofacitinib or Etanercept to accelerate clinical relevant dose reduction of non-steroidal anti-inflammatory drugs and treat-to-target guided minimization of intake of corticosteroids in patients with active Rheumatoid Arthrtis and an inadequate response to previous csDMARD therapy Überprüfung der Fähigkeit von Tofacitinib oder Etanercept, die Dosis von Nicht-Steroidalen Antirheumatika zu reduzieren und die Behandlungsziel-gesteuerte Verringerung der Einnahme von Glukokortikosteroiden bei Patienten mit aktiver Rheumatoider Arthritis und einem unzureichenden Ansprechen auf eine vorhergehende csDMARD-Therapie zu beschleunigen

Not yet recruiting
4
192
Europe
Film-coated tablet, Injection, Capsule, hard, Xeljanz, Enbrel, Celebrex
Fraunhofer-Institute for Translational Medicine and Pharmacology ITMP, Pfizer Pharma GmbH, Fraunhofer Gesellschaft e.V.
Patients with active Rheumatoid Arthritis Patienten mit aktiver Rheumatoider Arthritis, Patients with active Rheumatoid Arthritis Patienten mit aktiver Rheumatoider Arthritis, Diseases [C] - Immune System Diseases [C20]
 
 
2019-001754-25: Using adalimumab serum concentration to choose a subsequent biological treatment in rheumatoid arthritis patients failing adalimumab treatment

Not yet recruiting
4
84
Europe
Etanercepet, Rituximab, Abatacept, Tocilizumab, Sarilumab, Injection, Enbrel, Benepali, Erelzi Rituximab: mabthera, Rixathon, Truxima Abatacept: Orencia Tocilizumab: Roactemra Sarilumab: Kevzara
Reade, ZonMw
rheumatoid arthritis, Rheumatoid arthritis, Diseases [C] - Immune System Diseases [C20]
 
 
STARA, NCT01793519: Stopping TNF Alpha Inhibitors in Rheumatoid Arthritis

Active, not recruiting
4
290
US
Etanercept, Enbrel, Infliximab, Remicade, Adalimumab, Humira, Placebo
Georgetown University, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), University of Maryland, Baltimore, Washington D.C. Veterans Affairs Medical Center, Medstar Health Research Institute, Patient-Centered Outcomes Research Institute, Arthritis and Pain Associates of PG County, Arthritis & Rheumatism Associates, P.C., Rheumatology Associates of Baltimore, L.L.C., The Arthritis Clinic of Northern Virginia, P.C., Arthritis and Rheumatic Disease Associates, P.C.
Rheumatoid Arthritis
06/24
08/24
ChiCTR1900027001: The real word study of safety and efficacy of etanercept in psoriatic arthritis patients

Not yet recruiting
4
200
 
etanercept
The First Affiliated Hospital of China Medical University; The First Affiliated Hospital of China Medical University, None.
psoriatic arthritis
 
 
AcceleRAte, NCT04485325: Capability of Tofacitinib or Etanercept to Accelerate Tapering of NSAID and Treat-to-target Guided De-escalation of Corticosteroids in RA Patients

Completed
4
92
Europe
Tofacitinib, TOFA, Xeljanz, Etanercept, Enbrel, ETA
Dr. Frank Behrens, Pfizer
Rheumatic Arthritis
03/24
03/24
NCT05135312: Etanercept Therapy for Nails Psoriasis Monitoring With Noninvasive Imaging

Recruiting
4
10
US
Etanercept, Enbrel, OCT, Optical Coherence Tomography
OptiSkin Medical, Amgen
Psoriasis, Psoriatic Arthritis, Psoriatic Nail
08/22
08/22
TEEMS, NCT03813771: Targeted Treatment Early With Etanercept + Methotrexate vs.T2T Care for DMARD-naïve Early RA Patients Based on naïve T-cell Stratification

Not yet recruiting
4
106
Europe
Benepali, Etanercept, Sulfasalazine, Methotrexate, Hydroxychloroquine
University of Leeds, Samsung Bioepis Co., Ltd.
Rheumatoid Arthritis
02/23
02/23
BACH, NCT04985435: Better After CHoosing. Randomly Allocated or Patient Preference Based Treatment With Filgotinib or TNFi in RA

Recruiting
4
100
Europe
Filgotinib, Jyseleca, Anti-Tumor Necrosis Factor Alpha Drug (Product), Adalimumab (Humira) Etanercept (Enbrel), 50 patients will have a Free Choice between Filgotinib and anti TNF
R.Bos, Galapagos NV, Medical Centre Leeuwarden, Leiden University Medical Center
Rheumatoid Arthritis
03/23
04/23
NCT02713997: Anti-inflammatory Therapy to Improve Outcomes After TPIAT

Active, not recruiting
4
43
US
etanercept, Enbrel, Alpha 1-Antitrypsin, Aralast NP
University of Minnesota, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Pancreatitis, Chronic; Diabetes; Transplant
07/23
05/25
NCT02144857: Effects of Treatment With Biological Agents on Vascular and Cardiac Function in Psoriasis

Recruiting
4
200
Europe
etanercept, Enbrel, ustekinumab, Stelara, cyclosporine, Neoral, Secukinumab, Cosentyx, Apremilast, Otezla
University of Athens
Psoriasis
09/23
12/23
BIOTAPE, NCT05115903: Biologic Tapering Study of TNF Inhibitors in Axial Spondyloarthritis

Active, not recruiting
4
15
Canada
Tapered doses of TNFi, etanercept 50 mg every 10 days (75% of baseline dose), 14 days (50%), 30 days (25%), adalimumab 40 mg every 3 weeks (75%), 4 weeks (50%), 16 weeks (25%), certolizumab pegol 200 mg 3 weeks (75%), 4 weeks (50%), 16 weeks (25%), golimumab 50 mg every 6 weeks (75%), 8 weeks (50%), 16 weeks (25%), infliximab 5 mg/kg every 8 weeks (75%), 12 weeks (50%), 16 weeks (25%), Standard dose of TNFi, etanercept 50 mg every 7 days, adalimumab 40 mg every 2 weeks, certolizumab pegol 200 mg every 2 weeks, golimumab 50 mg every 4 weeks, infliximab 5 mg/kg every 6 weeks
University Health Network, Toronto
Axial Spondyloarthritis
07/24
08/24
COVER, NCT05080218: COVID-19 VaccinE Response in Rheumatology Patients

Recruiting
4
1000
US
Upadacitinib, Rinvoq, Abatacept, Orencia SQ, Secukinumab, Cosentyx, Tofacitinib, Xeljanz, TNF Inhibitor, Etanercept, Certolizumab, Golimumab SQ, Adalimumab, Canakinumab Injection, Ilaris, Baricitinib, Olumiant, Ixekizumab, Taltz
Jeffrey Curtis, University of Alabama at Birmingham, University of Nebraska, University of Pennsylvania, AbbVie, Bristol-Myers Squibb, Novartis, Eli Lilly and Company, Pfizer, Illumination Health
Rheumatoid Arthritis, Psoriatic Arthritis, Spondylarthritis
02/24
09/24
RECAST, NCT05164198: REduCed Dose of TNFi in Patients With Ankylosing SpondyliTis

Not yet recruiting
4
448
NA
Adalimumab and its biosimilars, Humira, Adaloce, Biological: Etanercept and its biosimilars, Enbrel, Eucept, Etalace, Golimumab, Simponi, Infliximab biosimilar, Remsima
Hanyang University Seoul Hospital, Linical Korea
Ankylosing Spondylitis, Axial Spondyloarthritis
10/24
10/24
RA-BRANCH, NCT04086745: A Study of Baricitinib in Participants With Rheumatoid Arthritis

Recruiting
4
1300
US
Baricitinib, LY3009104, TNF Inhibitor, Etanercept, Adalimumab
Eli Lilly and Company, Incyte Corporation
Rheumatoid Arthritis
12/24
02/26
NCT03976245: Advanced Therapeutics in Rheumatoid Arthritis (RA)

Recruiting
4
144
Canada
Etanercept, enbrel, Brenzys, tofacitinib, Xeljanz, Jakvinus
Lawson Health Research Institute, Academic Medical Organization of Southwestern Ontario
Rheumatoid Arthritis
03/25
03/25
RA-BRIDGE, NCT03915964 / 2018-003351-37: A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis

Active, not recruiting
4
2600
Europe, US, RoW
Baricitinib, LY3009104, TNF Inhibitor, Etanercept, Adalimumab
Eli Lilly and Company, Incyte Corporation
Rheumatoid Arthritis
04/25
02/26
ChiCTR2400081077: A multi-center randomized controlled clinical study of multi-target synergistic treatment for chronic active antibody-mediated rejection

Not yet recruiting
4
90
 
Patients were successfully screened with intravenous rituximab (100mg/m2), 4 plasmapheresis/IVIg sessions were started 3 days later, with an interval of one day between each treatment, and intravenous rituximab (100mg/m2) was infused 3 days after the last treatment.; Patients were successfully screened with intravenous infusion of rituximab (100mg/m2), 4 plasmapheresis/IVIg sessions were started 3 days later, with an interval of one day between each treatment, and intravenous infusion of rituximab (100mg/m2) 3 days after the last treatment, 14 days later, tetanercept treatment was started at 240mg twice weekly for 3 months, and then 160mg tetatercept twice weekly for 3 months.
The First Affiliated Hospital of Xi'an Jiaotong University; The First Affiliated Hospital of Xi'an Jiaotong University, The First Affiliated Hospital of Xi'an Jiaotong University
Chronic active antibody-mediated rejection
 
 

Download Options